Twinrix Junior Vaccine Injection

hepatitis A + Hepatitis B vaccine
"360 Elisa, 10mcg/0.5ml"
GLAXOSMITHKLINE BIOLOGICALS S.A.
Pack size 1 Dose (0.5ml) Prefilled Syringe
Dispensing mode POM
Source BELGIUM
AgentGULF DRUG EST.
Retail Price 83.50 AED

Indications

Twinrix Junior Vaccine Injection is used for: active immunisation against hepatitis A and hepatitis B virus infection

Adult Dose

Standard schedule: The immunogenicity of TWINRIX (720/20) has been investigated using a 0, 1 and 6 month vaccination schedule in randomised clinical studies involving over 700 adult volunteers. Specific humoral antibodies (seropositivity) against HAV were elicited in: # 92-96% of vaccinees one month after the first dose # 97-100% of vaccinees one month after the second dose # 100% of vaccinees one month after the third dose. Seropositivity was defined as anti-HAV antibody titres >= 33 IU/L. Seroprotective levels of anti-HBs antibodies (titers >=10 IU/L) were elicited in: # 33.7% of vaccinees one month after the first dose # 83.9% of vaccinees one month after the second dose # 99.3% of vaccinees one month after the third dose. An anti-HBs antibody titre above 10 IU/L correlates with protection against hepatitis B infection. Rapid Schedule: The immunogenicity of TWINRIX (720/20) has also been investigated using a 0, 7, 21 day primary schedule plus a fourth dose at month 12 in a randomised clinical study involving over 400 adult volunteers, of whom 239 received TWINRIX (720/20). Specific humoral antibodies (seropositivity) against HAV were elicited in: # 100% of vaccinees one week after the third dose # 99.5% of vaccinees five weeks after the third dose # 100% of vaccinees one month after the fourth dose. Seroprotective levels of anti-HBs antibodies (titers >=10 IU/L) were elicited in: # 82% of vaccinees one week after the third dose # 85% of vaccinees five weeks after the third dose # 100% of vaccinees one month after the fourth dose.

Child Dose

Renal Dose

Administration

Contra Indications

Precautions

Pregnancy-Lactation

should be used during pregnancy only when clearly needed, and when the possible advantages outweigh the possible risks for the foetus. The effect on embryo-foetal, peri-natal and post-natal survival and development has not been prospectively evaluated in clinical trials.

Interactions

Adverse Effects

Side effects of hepatitis A + Hepatitis B vaccine : Gastrointestinal disorders: Common: gastrointestinal symptoms (such as diarrhoea, nausea, vomiting) General disorders and administration site conditions: Very common: pain and redness at the injection site, fatigue; Common: injection site reaction, malaise, swelling at the injection site; Uncommon: fever (≥ 37.5˚C); Rare: influenza like illness, chills Infections and infestations: Common: Viral infection; Uncommon: upper respiratory tract infection Blood and lymphatic system disorders: Rare: lymphadenopathy Metabolism and nutrition disorders: Rare: decreased appetite Nervous system disorders: Very common: headache; Uncommon: dizziness; Rare: hypoaesthesia, paraesthesia Vascular disorders: Rare: hypotension Skin and subcutaneous tissue disorders: Rare: rash, pruritus; Very rare: urticaria Musculoskeletal and connective tissue disorders: Uncommon: myalgia; Rare: arthralgia

Mechanism of Action

Note

Twinrix Junior Vaccine "360 Elisa, 10mcg/0.5ml" Injection manufactured by GLAXOSMITHKLINE BIOLOGICALS S.A.. Its generic name is hepatitis A + Hepatitis B vaccine. Twinrix Junior Vaccine is availble in United Arab Emirates. Farmaco UAE drug index information on Twinrix Junior Vaccine Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of hepatitis A + Hepatitis B vaccine :